PEG-MGF

What it is

PEG-MGF (pegylated mechano growth factor) is a synthetic peptide based on a splice variant of insulin-like growth factor-1 (IGF-1Ec, also called mechano growth factor or MGF). The “PEG” refers to polyethylene glycol modification intended to extend the peptide’s half-life.

Mechano growth factor was identified as an IGF-1 splice variant expressed in tissue in response to mechanical stimulation.

PEG-MGF is not FDA-approved for any use in the United States and has only limited preclinical research.

Mechanism of action

Proposed mechanisms come from laboratory and animal research. MGF has been studied in animal and cell models of tissue response to mechanical loading. Whether PEG-MGF has any effect when given exogenously has not been established. PEGylation is reported to extend half-life from minutes (native MGF) to hours.

Clinical evidence

Research on PEG-MGF is limited to preclinical studies. Human clinical trials evaluating it are absent, and its effectiveness and safety in people have not been established.

Why we don’t prescribe it at The Tide

The Tide does not prescribe or offer PEG-MGF. Its evidence base consists of a hypothesis and limited preclinical data:

• No published human clinical trials have evaluated PEG-MGF
• Its effects in people, if any, are unknown
• Its long-term safety has not been studied

The hypothesis behind PEG-MGF has not been tested in the kind of clinical research needed to evaluate it.

Side effects and contraindications

Human safety has not been established, and long-term effects are unknown. IGF-1-related growth signaling raises theoretical concerns in people with cancer or growth-related conditions, and safety data are lacking for pregnancy and breastfeeding. Products sold outside regulated channels (for example, as “research peptides”) may vary in purity, dose, and sterility.